Literature DB >> 11395213

Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization.

L Reyes1, J Hartikka, V Bozoukova, L Sukhu, W Nishioka, G Singh, M Ferrari, J Enas, C J Wheeler, M Manthorpe, M K Wloch.   

Abstract

Antigen specific immune responses were characterized after intramuscular immunization of BALB/c mice with 5 antigen encoding plasmid DNAs (pDNAs) complexed with Vaxfectin, a cationic lipid formulation. Vaxfectin increased IgG titers for all of the antigens with no effect on the CTL responses to the 2 antigens for which CTL assays were performed. Both antigen specific IgG1 and IgG2a were increased, although IgG2a remained greater than IgG1. Furthermore, Vaxfectin had no effect on IFN-gamma or IL-4 production by splenocytes re-stimulated with antigen, suggesting that the Th1 type responses typical of intramuscular pDNA immunization were not altered. Studies with IL-6 -/- mice suggest that the antibody enhancement is IL-6 dependent and results in a correlative increase in antigen specific antibody secreting cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11395213     DOI: 10.1016/s0264-410x(01)00090-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Synergy between cationic lipid and co-lipid determines the macroscopic structure and transfection activity of lipoplexes.

Authors:  Marilyn E Ferrari; Denis Rusalov; Joel Enas; Carl J Wheeler
Journal:  Nucleic Acids Res       Date:  2002-04-15       Impact factor: 16.971

Review 2.  Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection.

Authors:  Crispin R Dass
Journal:  J Mol Med (Berl)       Date:  2004-06-23       Impact factor: 4.599

3.  A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.

Authors:  G Hermanson; V Whitlow; S Parker; K Tonsky; D Rusalov; M Ferrari; P Lalor; M Komai; R Mere; M Bell; K Brenneman; A Mateczun; T Evans; D Kaslow; D Galloway; P Hobart
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

Review 4.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

5.  Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia.

Authors:  Viraj Kulkarni; Margherita Rosati; Antonio Valentin; Rashmi Jalah; Candido Alicea; Lei Yu; Yongjun Guan; Xiaoying Shen; Georgia D Tomaras; Celia LaBranche; David C Montefiori; Carmela Irene; Rajasekhar Prattipati; Abraham Pinter; Sean M Sullivan; George N Pavlakis; Barbara K Felber
Journal:  Hum Vaccin Immunother       Date:  2013-07-02       Impact factor: 3.452

6.  A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.

Authors:  Michael A McVoy; Ronzo Lee; Frances M Saccoccio; Jukka Hartikka; Larry R Smith; Rohit Mahajan; Jian Ben Wang; Xiaohong Cui; Stuart P Adler
Journal:  Vaccine       Date:  2015-10-24       Impact factor: 3.641

7.  A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes.

Authors:  Ronald L Veselenak; Mark Shlapobersky; Richard B Pyles; Qun Wei; Sean M Sullivan; Nigel Bourne
Journal:  Vaccine       Date:  2012-10-04       Impact factor: 3.641

Review 8.  Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.

Authors:  Aseem Pandey; Neetu Singh; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Hum Vaccin       Date:  2010-02-24

9.  Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus.

Authors:  Chien-Hsiung Pan; Gretchen S Jimenez; Nitya Nair; Qun Wei; Robert J Adams; Fernando P Polack; Alain Rolland; Adrián Vilalta; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-06-04

10.  Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.

Authors:  Jukka Hartikka; Vesselina Bozoukova; Jane Morrow; Denis Rusalov; Mark Shlapobersky; Qun Wei; Sou Boutsaboualoy; Ming Ye; Mary K Wloch; John Doukas; Sean Sullivan; Alain Rolland; Larry R Smith
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.